Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CACNA1C antisense RNA 3 (CACNA1C-AS3)
- Target
- CACNA1C-AS3
- Molecular classification
- Long non-coding RNA (lncRNA), Other (non-protein-coding nucleotide sequence)
01
Overview
CACNA1C antisense RNA 3 (CACNA1C-AS3) is a long non-coding RNA located in the human genome, canonically associated with the CACNA1C locus. CACNA1C-AS3 is 444 nucleotides long and is annotated in multiple RNA databases[1]. It has been implicated in post-transcriptional regulation of genes related to calcium channels. CACNA1C-AS3 shows altered expression or mutational profiles in some cancers, notably stomach adenocarcinoma, where mutations are associated with poor prognosis[1]. Mutational analysis of this lncRNA has revealed effects on its secondary structure and potentially its expression or function[1]. Its biological roles remain under investigation, but it serves as a potential biomarker rather than a direct therapeutic target.
- Other names
- CACNA1C-AS3lnc-CACNA1C-3
02
Biological functions
Regulation of gene expression in calcium channel-related pathwaysPotential involvement in survival outcomes of stomach adenocarcinoma, possibly via post-transcriptional regulation or modulation of transcript stabilityMay interact with co-mutated lncRNAs (such as HOTAIRM1), suggesting possible regulatory network effectsPossible influence on the secondary structure and functional effects due to mutation-induced changes in minimum free energy
03
Disease associations
Cancer (prognostic biomarker in stomach adenocarcinoma; mutations correlated with poorer survival)Other disease associations are speculative; expression and functional studies are limited
04
Biomarkers
Mutational status of CACNA1C-AS3 (linked with prognostic relevance in stomach adenocarcinoma)Expression levels may be studied as biomarkers in future research, but currently only mutation and expression have been reported as research biomarkers
Beyond the preview
Go deeper on CACNA1C antisense RNA 3 (CACNA1C-AS3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CACNA1C antisense RNA 3 (CACNA1C-AS3).